Condition
Lenacapavir
Total Trials
3
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
2Total
Not Applicable (1)
P 2 (1)
Trial Status
Withdrawn1
Recruiting1
Not Yet Recruiting1
Clinical Trials (3)
Showing 3 of 3 trials
NCT07518914Not ApplicableRecruiting
Protecting Against Lenacapavir Misinformation With Young Women in Gauteng, South Africa ( PROTECT-L)
NCT07402044Not Yet Recruiting
CABOTEGRAVIR/LENACAPAVIR DUAL LONG ACTING THERAPY (COHORT IMEA 074)
NCT06657885Phase 2Withdrawn
CAbotégravir LENacapavir DUal Long Acting
Showing all 3 trials